Aurinia Pharmaceuticals Inc. Share Price Toronto S.E.
Equities
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 227M 0 17.51B | Sales 2025 * | 282M 0 21.76B | Capitalization | 827M 0 63.78B |
---|---|---|---|---|---|
Net income 2024 * | 9M - 694M | Net income 2025 * | 71M - 5.47B | EV / Sales 2024 * | 1.9 x |
Net cash position 2024 * | 395M 0 30.47B | Net cash position 2025 * | 448M 0 34.52B | EV / Sales 2025 * | 1.34 x |
P/E ratio 2024 * |
100
x | P/E ratio 2025 * |
12.3
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.93% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 15/06/93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
Robert Foster
FOU | Founder | 65 | 15/06/93 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 15/06/93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 25/06/19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 28/04/19 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 127B | |
+24.67% | 117B | |
+25.44% | 27.67B | |
-17.74% | 20.33B | |
-15.17% | 16.79B | |
-15.21% | 15.63B | |
+11.91% | 14.84B | |
-47.10% | 14.65B | |
+54.50% | 14.43B |